- Home
- NVRI vs OCS Comparison
NVRI vs OCS Comparison
Compare NVRI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVRI | OCS |
|---|---|---|
| Founded | 1853 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVRI | OCS |
|---|---|---|
| Price | $20.72 | $22.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | ★ 2.0M | 423.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,240,358,000.00 | N/A |
| Revenue This Year | $3.87 | $466.06 |
| Revenue Next Year | $3.70 | $479.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.70 | $16.00 |
| 52 Week High | $21.42 | $34.48 |
Technical Indicators
Market Signals| Indicator | NVRI | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 32.75 |
| Support Level | $17.56 | $18.26 |
| Resistance Level | N/A | $29.27 |
| Average True Range (ATR) | 0.67 | 2.27 |
| MACD | 0.15 | -0.56 |
| Stochastic Oscillator | 75.85 | 18.63 |
Price Performance
Historical ComparisonAbout NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.